866-997-4948(US-Canada Toll Free)

Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 62 Pages

Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Pipeline Review, H2 2016

Summary

Global Markets Directs, Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Pipeline Review, H2 2016, provides in depth analysis on Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted pipeline therapeutics.

The report provides comprehensive information on the Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37)
- The report reviews Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics and enlists all their major and minor projects
- The report assesses Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) Overview 7
Therapeutics Development 8
Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Products under Development by Stage of Development 8
Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Products under Development by Therapy Area 9
Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Products under Development by Indication 10
Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Products under Development by Companies 14
Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Products under Development by Universities/Institutes 16
Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Therapeutics Assessment 18
Assessment by Monotherapy/Combination Products 18
Assessment by Mechanism of Action 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Companies Involved in Therapeutics Development 24
AstraZeneca Plc 24
Cantex Pharmaceuticals Inc 25
Chiesi Farmaceutici SpA 26
Kyorin Pharmaceutical Co Ltd 27
Polyphor Ltd 28
Proteo Inc 29
Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Drug Profiles 30
ANV-201 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
AZD-9668 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
brevenal - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
dociparstat sodium - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
KRP-109 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
POL-6014 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Polysaccharides to Inhibit P-Selectin and HLE for Age-Related Macular Degeneration - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Small Molecule 1 to Inhibit Neutrophil Elastase for Immunology, Oncology and Respiratory Disorders - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Small Molecule 2 to Inhibit Neutrophil Elastase for Immunology, Oncology and Respiratory Disorders - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Small Molecule to Inhibit Neutrophil Elastase for Respiratory Diseases - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
tiprelestat - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Dormant Projects 46
Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Discontinued Products 50
Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Featured News & Press Releases 51
Jun 06, 2016: Proteo receives US$ 1 million grant for a new Elafin drug formulation 51
Mar 02, 2016: New Patent Issued to Cantex Pharmaceuticals for Its Lead Product Candidate in the Treatment of Thrombocytopenia and Neutropenia 51
Sep 01, 2015: Polyphor extends clinical development portfolio by advancing its inhaled elastase inhibitor POL6014 for lung diseases to Phase I 51
Jun 01, 2015: Cantex Pharmaceuticals Announces Poster Presentation at ASCO 2015 Indicating Potential Efficacy of CX-01 52
May 18, 2015: Cantex Pharmaceuticals Announces Efficacy and Safety Data from Study of CX-01 in AML to be Presented at 2015 ASCO Annual Meeting 53
Mar 12, 2015: Elafin combined with cyclosporine promises to overcome limitations of cyclosporine for preventing irreversible damage to transplanted organs 54
Nov 21, 2014: Final Analysis of the Phase II Clinical Study on Elafin in coronary artery bypass surgery completed 54
May 20, 2014: $ 4.8 Million Funding for Proteos Advanced Orphan Drug Development 55
Nov 08, 2013: Proteo, Inc. / Proteo Biotech AG: Patient Recruitment and Treatment in Elafin CABG Phase II Clinical Trial Completed 55
Mar 20, 2013: Proteo's Elafin Obtains FDA Orphan Drug Designation For Prevention Of Inflammatory Complications Of Transthoracic Esophagectomy 56
Jan 10, 2013: Proteo's Elafin Receives FDA Orphan Drug Designation For Treatment Of Pulmonary Arterial Hypertension 56
Dec 11, 2012: Proteo Announces Patient Recruitment For EMPIRE Study Of Elafin Surpassed Expectations 57
Jun 27, 2012: Researchers Provide Further Rationale For Proteo's Elafin Treatment In Newborn Infants 58
Jun 22, 2012: Proteo Provides Update On Phase II Study Of Elafin In Coronary Bypass Surgery 58
Dec 06, 2011: Proteo And Its Subsidiary Announce Major Advances In Elafin Development Program 59
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 61
Disclaimer 62

List of Tables
Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Products under Development by Companies, H2 2016 15
Number of Products under Investigation by Universities/Institutes, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Assessment by Monotherapy/Combination Products, H2 2016 18
Number of Products by Stage and Mechanism of Action, H2 2016 19
Number of Products by Stage and Route of Administration, H2 2016 21
Number of Products by Stage and Molecule Type, H2 2016 23
Pipeline by AstraZeneca Plc, H2 2016 24
Pipeline by Cantex Pharmaceuticals Inc, H2 2016 25
Pipeline by Chiesi Farmaceutici SpA, H2 2016 26
Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2016 27
Pipeline by Polyphor Ltd, H2 2016 28
Pipeline by Proteo Inc, H2 2016 29
Dormant Projects, H2 2016 46
Dormant Projects (Contd..1), H2 2016 47
Dormant Projects (Contd..2), H2 2016 48
Dormant Projects (Contd..3), H2 2016 49
Discontinued Products, H2 2016 50

List of Figures
Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Top 10 Indication, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 13
Assessment by Monotherapy/Combination Products, H2 2016 18
Number of Products by Stage and Mechanism of Actions, H2 2016 19
Number of Products by Routes of Administration, H2 2016 20
Number of Products by Stage and Routes of Administration, H2 2016 20
Number of Products by Molecule Types, H2 2016 22
Number of Products by Stage and Molecule Type, H2 2016 22

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *